Our attorneys have filed a mass tort lawsuit on behalf of sufferers who took the blood thinner Xarelto (rivaroxaban) and suffered critical bleeding events. Pharmaceutical businesses, including the makers of Xarelto, have a duty to ensure that their drugs are reasonably safe for use – and failure to accomplish so might be grounds for compensation. Our lawyers are working challenging to get those hurt by the drug the compensation they’re entitled to.
Whilst bleeding is really a frequent complication related with anticoagulants, it has been alleged that Xarelto is more harmful than standard blood thinners due to the fact no antidote exists to reverse its blood-thinning effects. This signifies that, within the occasion of an emergency, sufferers could be at risk for irreversible bleeding troubles, which includes life-threatening internal and gastrointestinal hemorrhaging.
In case you or a loved one suffered a significant bleeding event soon after taking Xarelto, you may have legal recourse. For more details, make contact with us these days to possess your case reviewed, cost-free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for past and future healthcare bills, lost wages, pain and suffering and, in situations of death, funeral expenses. Furthermore, they may be in search of punitive damages, https://myhati.net/ which are typically awarded to punish the defendant and deter other organizations from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike classic anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Since of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding within the event of an emergency. Plaintiffs in the lawsuits allege critical and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and health-related staff were not properly made aware of methods to stabilize and treat a Xarelto user within the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to significant bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting.
Visit this page for more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.